Immuneering (IMRX) Total Current Liabilities: 2020-2024
Historic Total Current Liabilities for Immuneering (IMRX) over the last 4 years, with Sep 2024 value amounting to $6.9 million.
- Immuneering's Total Current Liabilities rose 23.08% to $6.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $6.9 million, marking a year-over-year increase of 23.08%. This contributed to the annual value of $7.8 million for FY2023, which is 2.59% down from last year.
- Latest data reveals that Immuneering reported Total Current Liabilities of $6.9 million as of Q3 2024, which was up 2.05% from $6.8 million recorded in Q2 2024.
- In the past 5 years, Immuneering's Total Current Liabilities registered a high of $8.1 million during Q4 2022, and its lowest value of $2.3 million during Q4 2020.
- In the last 3 years, Immuneering's Total Current Liabilities had a median value of $5.6 million in 2023 and averaged $6.0 million.
- As far as peak fluctuations go, Immuneering's Total Current Liabilities soared by 149.74% in 2021, and later fell by 22.51% in 2023.
- Quarterly analysis of 5 years shows Immuneering's Total Current Liabilities stood at $2.3 million in 2020, then surged by 149.74% to $5.6 million in 2021, then surged by 42.96% to $8.1 million in 2022, then dropped by 2.59% to $7.8 million in 2023, then climbed by 23.08% to $6.9 million in 2024.
- Its Total Current Liabilities stands at $6.9 million for Q3 2024, versus $6.8 million for Q2 2024 and $5.2 million for Q1 2024.